# Targeted drug delivery with nanoparticles

> A 3D-style graphical abstract of nanoparticle drug delivery: the anatomy of a multifunctional liposomal carrier (targeting ligands, PEG corona, bilayer, drug payloads, imaging agent), passive tumour targeting through the EPR effect, and active targeting with receptor-mediated endocytosis and triggered drug release.

- Page: https://www.labcanvas.com/templates/nanomaterial-applications/targeted-drug-delivery-nanoparticles
- Open in the LabCanvas editor (LabCanvas account): https://www.labcanvas.com/editor.html?template=targeted-drug-delivery-nanoparticles
- Updated: 2026-10-14
- Category: Nanomaterial applications
- Method: Drug delivery
- Product: Ligand-targeted, PEGylated nanocarriers (typically 50–200 nm)
- Figure: 1800 × 1300 px, 193 editable layers

## Steps

1. **Circulation**: PEG corona limits protein adsorption and immune clearance
2. **Passive targeting**: Extravasation through leaky tumour vessels (EPR effect)
3. **Active targeting**: Ligand–receptor binding, endocytosis, triggered release

## Uses

- Nanomedicine papers and reviews
- Teaching passive and active targeting

## References

1. Peer et al., “Nanocarriers as an emerging platform for cancer therapy”, Nat. Nanotechnol. 2007. https://doi.org/10.1038/nnano.2007.387 (review)

Credit: Overview after Peer et al., Nat. Nanotechnol. 2007 (doi:10.1038/nnano.2007.387). The carrier, vessels and cell are schematic, not to scale; sizes and pH values are typical literature ranges.

## Questions

**What does the “Targeted drug delivery with nanoparticles” template show?** A 3D-style graphical abstract of nanoparticle drug delivery: the anatomy of a multifunctional liposomal carrier (targeting ligands, PEG corona, bilayer, drug payloads, imaging agent), passive tumour targeting through the EPR effect, and active targeting with receptor-mediated endocytosis and triggered drug release.

**What are the steps shown in “Targeted drug delivery with nanoparticles”?** 1. Circulation: PEG corona limits protein adsorption and immune clearance. 2. Passive targeting: Extravasation through leaky tumour vessels (EPR effect). 3. Active targeting: Ligand–receptor binding, endocytosis, triggered release.

**Which papers is “Targeted drug delivery with nanoparticles” based on?** Peer et al., “Nanocarriers as an emerging platform for cancer therapy”, Nat. Nanotechnol. 2007 (doi:10.1038/nnano.2007.387).

**Can I edit the “Targeted drug delivery with nanoparticles” template?** Yes. Open it in the LabCanvas editor: all 193 layers are editable. Change the text, colours and layout, then export PNG, TIFF, SVG or PDF.

**Do I need an account to use this template?** Not to view it here. To open and edit it, sign in to LabCanvas or create a free account (the free plan keeps one design of each kind). Downloading the figure is part of LabCanvas Pro (US$19 a month or US$199 a year).